-
1.发明申请POLYMORPHISMS IN PON1 ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION 审中-公开PON1中的多态性与XIMELAGATRAN或TACRINE ADMINISTRATION之后的亚胺氨基转移酶水平相关公开(公告)号：US20090029367A1
公开(公告)日：2009-01-29
申请号：US12067864
申请日：2006-10-03
申请人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
发明人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K38/07 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the PON1 gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran or tacrine administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran or tacrine administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
摘要翻译： 本发明涉及向某些合适的患者施用药学上可用的抗凝药物的方法和鉴定那些适合接受药物的患者的方法。 特别地，本发明围绕在PON1基因中的某些SNP之间的关联的识别以及在施用西他加他汀或他克林给药后对丙氨酸氨基转移酶（ALAT）水平升高的敏感性。 因此，本发明涉及用于预测西咪加群或他克林给药后升高的ALAT的易感性的方法以及向某些合适的患者施用药学上可用的抗凝药物的方法。
-
2.发明申请ASSOCIATION BETWEEN HLA-DRBI*07 ALLELE AND SUSCEPTIBILY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION 审中-公开HLA-DRBI * 07之间的关系可以提高XIMELAGATRAN管理层面的水平公开(公告)号：US20090036424A1
公开(公告)日：2009-02-05
申请号：US12067867
申请日：2006-10-03
申请人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
发明人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
IPC分类号： A61K31/397 , C12Q1/68
CPC分类号： C12Q1/6881 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between HLA-DRB1*07 allele and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
摘要翻译： 本发明涉及向某些合适的患者施用药学上可用的抗凝药物的方法和鉴定那些适合接受药物的患者的方法。 特别地，本发明包括确定HLA-DRB1 * 07等位基因与施用西咪加群后丙氨酸转氨酶（ALAT）水平升高的易感性之间的关联。 因此，本发明涉及用于预测西替加联给药后升高的ALAT的易感性的方法以及向某些合适的患者施用药学上可用的抗凝药物的方法。
-
3.发明申请POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT 审中-公开MGST3中的多态性与XIMELAGATRAN治疗后的高级ALAT水平相关公开(公告)号：US20090054394A1
公开(公告)日：2009-02-26
申请号：US12067863
申请日：2006-10-03
申请人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
发明人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
IPC分类号： C12Q1/68 , A61K31/397 , A61P9/00
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the MGST3 gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
摘要翻译： 本发明涉及向某些合适的患者施用药学上可用的抗凝药物的方法和鉴定那些适合接受药物的患者的方法。 特别地，本发明包括鉴定MGST3基因中某些SNP之间的关联以及施用西咪加群后对丙氨酸氨基转移酶（ALAT）的增加水平的敏感性。 因此，本发明涉及用于预测西替加联给药后升高的ALAT的易感性的方法以及向某些合适的患者施用药学上可用的抗凝药物的方法。
-
4.发明申请SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION 审中-公开在APOB基因中的SNPS，并且不具有提高XIMELAGATRAN管理水平的水平公开(公告)号：US20090227559A1
公开(公告)日：2009-09-10
申请号：US12067858
申请日：2006-10-03
申请人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
发明人： Olof Bengtsson , Ellen Brown , Stefan Carlsson , Neil James Gibson , Ansar Jawaid , Andreas Kindmark , Ruth Eleanor March
IPC分类号： A61K31/397 , C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the apoB gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
摘要翻译： 本发明涉及向某些合适的患者施用药学上可用的抗凝药物的方法和鉴定那些适合接受药物的患者的方法。 特别地，本发明包括鉴定apoB基因中的某些SNP与施用西咪加群之后丙氨酸氨基转移酶（ALAT）水平升高的易感性之间的关联。 因此，本发明涉及用于预测西替加联给药后升高的ALAT的易感性的方法以及向某些合适的患者施用药学上可用的抗凝药物的方法。
-
-
-
搜索结果
4 条记录 (耗时 0.027 秒)
